Anika Therapeutics PE Ratio 2006-2021 | ANIK

Current and historical p/e ratio for Anika Therapeutics (ANIK) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Anika Therapeutics PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Anika Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 41.66 0.00
2021-06-30 43.29 $-0.90 0.00
2021-03-31 40.79 $-1.89 0.00
2020-12-31 45.26 $-1.85 0.00
2020-09-30 35.39 $-0.47 0.00
2020-06-30 37.73 $0.62 60.85
2020-03-31 28.91 $1.83 15.80
2019-12-31 51.85 $1.90 27.29
2019-09-30 54.89 $2.16 25.41
2019-06-30 40.62 $2.05 19.81
2019-03-31 30.24 $2.06 14.68
2018-12-31 33.61 $1.29 26.05
2018-09-30 42.18 $1.28 32.95
2018-06-30 32.00 $1.21 26.45
2018-03-31 49.72 $1.29 38.54
2017-12-31 53.91 $2.12 25.43
2017-09-30 58.00 $2.13 27.23
2017-06-30 49.34 $2.26 21.83
2017-03-31 43.44 $2.07 20.99
2016-12-31 48.96 $2.15 22.77
2016-09-30 47.85 $2.33 20.54
2016-06-30 53.65 $2.29 23.43
2016-03-31 44.72 $2.23 20.05
2015-12-31 38.16 $2.01 18.99
2015-09-30 31.83 $1.80 17.68
2015-06-30 33.03 $1.65 20.02
2015-03-31 41.17 $1.74 23.66
2014-12-31 40.74 $2.48 16.43
2014-09-30 36.66 $2.41 15.21
2014-06-30 46.33 $2.34 19.80
2014-03-31 41.10 $2.14 19.21
2013-12-31 38.16 $1.38 27.65
2013-09-30 23.89 $1.25 19.11
2013-06-30 17.00 $1.03 16.50
2013-03-31 14.52 $0.89 16.31
2012-12-31 9.94 $0.82 12.12
2012-09-30 15.02 $0.72 20.86
2012-06-30 13.59 $0.83 16.37
2012-03-31 12.54 $0.74 16.95
2011-12-31 9.80 $0.62 15.81
2011-09-30 5.44 $0.51 10.67
2011-06-30 7.12 $0.38 18.74
2011-03-31 8.96 $0.29 30.90
2010-12-31 6.67 $0.32 20.84
2010-09-30 6.01 $0.28 21.46
2010-06-30 5.89 $0.32 18.41
2010-03-31 7.11 $0.32 22.22
2009-12-31 7.63 $0.32 23.84
2009-09-30 6.50 $0.36 18.06
2009-06-30 4.75 $0.33 14.39
2009-03-31 4.59 $0.32 14.34
2008-12-31 3.04 $0.32 9.50
2008-09-30 7.22 $0.37 19.51
2008-06-30 8.59 $0.43 19.98
2008-03-31 8.48 $0.48 17.67
2007-12-31 14.55 $0.54 26.94
2007-09-30 20.81 $0.48 43.35
2007-06-30 15.19 $0.44 34.52
2007-03-31 12.37 $0.44 28.11
2006-12-31 13.27 $0.41 32.37
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.601B $0.130B
Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00